Last reviewed · How we verify

Aeras — Portfolio Competitive Intelligence Brief

Aeras pipeline: 2 marketed, 0 filed, 0 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 5 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
BCG Tice BCG Tice marketed
Candida Skin Test Antigen Candida Skin Test Antigen marketed Diagnostic antigen / Immunological test Immunology / Diagnostics

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. CanSino Biologics Inc. · 2 shared drug classes
  2. University of Oxford · 2 shared drug classes
  3. London School of Hygiene and Tropical Medicine · 2 shared drug classes
  4. Aga Khan University · 1 shared drug class
  5. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 1 shared drug class
  6. Asoc. Prof. Erdoğan Selçuk Şeber · 1 shared drug class
  7. Alba Maria Ropero · 1 shared drug class
  8. Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Aeras:

Cite this brief

Drug Landscape (2026). Aeras — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aeras. Accessed 2026-05-14.

Related